OncoC4

OncoC4, a private, clinical-stage biopharmaceutical company headquartered in Rockville, Maryland, USA, is dedicated to the discovery and development of innovative biologics for cancer treatment. OncoC4 was established as a spin-off following Merck's announcement of the acquisition of OncoImmune in December 2020. The new company retained assets excluding CD24Fc and received funding from Merck to advance its best-in-class and first-in-class immuno-oncology pipeline. ONC-392, OncoC4’s lead clinical candidate, is a next-generation anti-CTLA-4 antibody that mitigates immune-related adverse events in cancer immunotherapy. OncoC4’s pipeline represents an emerging therapeutic paradigm in the industry, targeting not only adaptive immune checkpoints such as CTLA-4 and PD-L1 but also the innate immune checkpoint CD24-Siglec 10 discovered by OncoC4’s founders. OncoC4’s technology platform encompasses humanized antibodies, bispecific antibodies, and antibody-drug conjugates.